As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will has difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

A b s t r a c t

Nanoparticles (NPs) consisting of a magnetic Fe3O4 core and a nickel(II)-doped silica shell were prepared and are shown to be viable materials for selective magnetic extraction of trace quantities of the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, erlotinib and sunitinib. The NPs were characterized by scanning electron microscopy, transmission electron microscopy, DLS and XRD analysis, and the results revealed a uniform in size (with a typical diameter of 40 nm) and a core-shell structure. The magnetic nanoadsorbent displays good affinity of the TKIs, probably because of the affinity between the Ni(II) ions of the NPs with the nitrogen atoms in the TKIs. The magnetism of the NPs enables them to be quickly separated from serum and cerebrospinal fluid samples. Imidazole, with its higher affinity for Ni(II) than that of the TKIs, was used for desorption of the TKIs from the NPs prior to their quantification by HPLC with UV detection. The detection limits are as low as 200, 480, 130, and 250 ng·L‾1 for imatinib, sunitinib, erlotinib, and nilotinib, respectively. The intra-day precisions (RSDs) were lower than 4.0 %. The method displays a wide linear range. It was applied to the determination of TKIs in (spiked) human serumand cerebrospinal fluid and gave recoveries in the range from 94.6 to 98.6 %.

 

 

Authors

Mehri Ghazaghi & Hassan Zavvar Mousavi & Hamid Shirkhanloo & Alimorad Rashidi

Acknowledgments

The authors would like to express their appreciation to the Semnan University Research Council for financial support of this study. The authors also thank Dr. Moazeni (Tehran, Iran, parsianpharma.co) for providing studied drugs.

Download Paper

Contact us

Publisher:AMECJ publisher with the License number of 83095 From the Ministry of Guidance, Iran. To see the Certificate please click here.

Madadkaran Alley,Farjam St., Shahnazari Ave, Mirdamad, 

Tehran, Iran     P: 1545653718